

RECEIVED

MAR 15 2002




00270

5/3/02
33
3/10/02PATO/SS/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TECH CENTER 1600/2000

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL
FORM

(to be used for all correspondence after initial filing)

Application Number	09/913,911
Filing Date	08/21/2001
First Named Inventor	Daniela Santoli et al
Group Art Unit	1633
Examiner Name	
Attorney Docket Number	WST88AUSA

Total Number of Pages in This Submission

5

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
- ☐ Fee Attached
- ☐ Amendment / Reply
- ☐ After Final
- ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
- ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter

☒ Other Enclosure(s) (please identify below):

Copies of (3) documents are attached

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Mary E. Bak, Esquire Howson and Howson
Signature	<i>Mary E. Bak</i>
Date	<i>March 5, 2002</i>

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 03/05/2002

Typed or printed name	Debra N. Gerstemeier
Signature	<i>Debra N. Gerstemeier</i>
Date	<i>3-5-2002</i>

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



00270

PATENT TRADEMARK OFFICE

WST88AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IDS/#5
3/18/02

In re the Application of

) Group Art Unit: 1633

Daniela Santoli et al

) Examiner:

RECEIVED

Appln. No. 09/913,911

MAR 15 2002

Filed: August 21, 2001

TECH CENTER 1600/2900

For: METHOD OF MODIFYING
CYTOTOXIC CELLS AND USES
THEREOF

) March 5, 2002

Assistant Commissioner for Patents
Washington, DC 20231SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants submit to the Examiner the attached Form PTO/SB/08A/B document listing and this paper pursuant to 37 CFR §1.56 and § 1.97-1.98. Form PTO/SB/08A/B is attached and copies of the references are enclosed herewith.

According to 37 CFR §1.97(c) and §1.97(e), Applicants and the undersigned attorney hereby certify that each item of information contained herein was cited in the Supplementary European Search Report mailed on February 4, 2002 in corresponding European Patent Application No. 00911919.9. A copy of the Supplementary European Search Report is enclosed together with copies fo the documents not previously submitted.

CERTIFICATE UNDER 37 CFR §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: the Assistant Commissioner for Patents, Washington, DC 20231 on March 5, 2002.

Signature Typed or printed name Debra N. Gerstemeier

This Supplemental Information Disclosure Statement is submitted within three months of issuance of the above Supplementary European Search Report and prior to receipt of a first Office Action on the merits. Therefore, no fees are believed due. However, the Director of the U. S. Patent and Trademark Office is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees paid on the filing, or during prosecution of this application to Deposit Account No. 08-3040.

The Examiner is respectfully requested to consider the documents identified in this paper and in the attached Form PTO/SB/08A/B during the course of the examination of this application.

Respectfully submitted,

HOWSON AND HOWSON
Attorneys for the Applicants

By Mary E. Bak
Mary E. Bak
Registration No. 31,215
Spring House Corporate Center
Box 457
Spring House, PA 19477
Telephone: (215) 540-9206
Telefacsimile: (215) 540-5818


RECEIVED

MAR 15 2002

TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Please type a plus sign (+) inside this box → ☐

Substitute for Form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 				Complete if Known	
				Application Number	09/913,911
				Filing Date	August 21, 2001
				First Named Inventor	Daniela Santoli et al
				Group Art Unit	1633
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	WST88AUSA

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
		Office ³	Number ⁴	Kind Code ² (if known)				
	AN	WO	WO95/27722	A1	K. Grabstein	10/19/1995		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

RECEIVED

MAR 15 2002

TECH CENTER 1600/2900

PTO/SB/08B (08-00)

Please type a plus sign (+) inside this box → ☐

Substitute for Form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	09/913,911
				Filing Date	August 21, 2001
				First Named Inventor	Daniela Santoli et al
				Group Art Unit	1633
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	WST88AUSA

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiners Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BBS	W. CARSON et al, "Interleukin (IL) 15 is a Novel Cytokine that Activates Human Natural Killer Cells via Components of the IL-2 Receptor", J. Exp. Med., 180(4):1395-1403 (1994)	
	BBT	H. KANEGANE et al, "Activation of Naive and Memory T Cells by Interleukin-15", Blood, 88(1):230-235 (July, 1996)	

Examiner Signature	Date Considered
-----------------------	--------------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.